Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
Ronan RousselSantiago Duran-GarcíaYilong ZhangSuneri ShahCarolyn DarmientoR Ravi ShankarGregory T GolmRaymond L H LamEdward A O'NeillIra GantzKeith D KaufmanSamuel S EngelPublished in: Diabetes, obesity & metabolism (2018)
When initiating insulin glargine therapy, continuation of sitagliptin, compared with discontinuation, resulted in a clinically meaningful greater reduction in HbA1c without an increase in hypoglycaemia. ClinicalTrials.gov Identifier: NCT02738879.